Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06029972
Registration number
NCT06029972
Ethics application status
Date submitted
1/09/2023
Date registered
8/09/2023
Date last updated
6/05/2024
Titles & IDs
Public title
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Query!
Scientific title
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
Query!
Secondary ID [1]
0
0
2022-501119-14
Query!
Secondary ID [2]
0
0
GS-US-457-6411
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PALEKONA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tilpisertib Fosmecarbil
Treatment: Drugs - Placebo
Experimental: Tilpisertib Fosmecarbil Dose A - Blinded Treatment Phase:
Participants will receive tilpisertib fosmecarbil Dose A for up to 12 weeks. An efficacy assessment will be performed at Week 12.
• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52.
Non-responder Treatment Phase:
• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose A for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug.
Experimental: Tilpisertib Fosmecarbil Dose B - Blinded Treatment Phase:
Participants will receive tilpisertib fosmecarbil Dose B for up to 12 weeks. An efficacy assessment will be performed at Week 12.
• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52.
Non-responder Treatment Phase:
• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose B for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug.
Experimental: Tilpisertib Fosmecarbil Dose C - Blinded Treatment Phase:
Participants will receive tilpisertib fosmecarbil Dose C for up to 12 weeks. An efficacy assessment will be performed at Week 12.
• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose C for up to Week 52.
Non-responder Treatment Phase:
• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose B for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug.
Placebo Comparator: Tilpisertib Fosmecarbil Placebo - Blinded Treatment Phase:
Participants will receive tilpisertib fosmecarbil placebo for up to 12 weeks. An efficacy assessment will be performed at Week 12.
• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose C for up to Week 52.
Non-responder Treatment Phase:
• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose A for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved Clinical Response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve Clinical Response at Non-responder Treatment Phase Week 12 will discontinue study drug.
Treatment: Drugs: Tilpisertib Fosmecarbil
Tablets administered orally
Treatment: Drugs: Placebo
Tablets administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of Participants Achieving Clinical Response Per Modified Mayo Clinic Score at Week 12
Query!
Assessment method [1]
0
0
Clinical Response is defined as a decrease from baseline of = 2 points and at least 30% in 3 components of the modified Mayo Clinic Score, Stool Frequency, Rectal Bleeding, and Endoscopic Findings, in addition to a = 1 point decrease from baseline in the Rectal Bleeding subscore or Rectal Bleeding subscore of = 1. The modified Mayo Clinic Score is a scoring system for assessment of UC activity and is composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), and stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 or more stools more than normal). Total score for modified Mayo Clinic Score ranges from 0 to 9 (sum of all subscores), with higher scores indicating higher disease activity.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Proportion of Participants Achieving Clinical Remission Per Modified Mayo Clinic Score at Week 12
Query!
Assessment method [1]
0
0
Clinical Remission is defined as a Stool Frequency subscore = 1 and not greater than baseline, Rectal Bleeding subscore of 0, and Endoscopic Findings subscore = 1 at Week 12. The modified Mayo Clinic Score is a scoring system for assessment of UC activity and is composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 or more stools more than normal). Total score for modified Mayo Clinic Score ranges from 0 to 9 (sum of all subscores), with higher scores indicating higher disease activity.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Proportion of Participants Achieving Endoscopic Response at Week 12
Query!
Assessment method [2]
0
0
Endoscopic Response is defined as an Endoscopic Findings subscore = 1 at Week 12. Endoscopic subscore is a part of the modified Mayo Clinic Score which is a scoring system for assessment of UC activity. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern), 2 = moderate disease (marked erythema, lack of vascular pattern, friability, erosions), and 3 = severe disease (spontaneous bleeding, ulceration). Higher scores indicate higher disease activity.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Proportion of Participants Achieving Histologic Endoscopic Mucosal Improvement at Week 12
Query!
Assessment method [3]
0
0
Histologic Endoscopic Mucosal Improvement is defined as an Endoscopic Findings subscore = 1 and Geboes score = 3.1 (indicating neutrophil infiltration in < 5% of crypts, no crypt destruction and no erosions, ulcerations, or granulation tissue). Endoscopic subscore is a part of the modified Mayo Clinic Score which is a scoring system for assessment of UC activity. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern), 2 = moderate disease (marked erythema, lack of vascular pattern, friability, erosions), and 3 = severe disease (spontaneous bleeding, ulceration). Geboes histologic remission is assessed using the Geboes histologic scores to identify histologic changes in ulcerative colitis. Possible scores are graded as Grade 0 to Grade 5, with higher grade representing higher levels of disease activity.
Query!
Timepoint [3]
0
0
Week 12
Query!
Secondary outcome [4]
0
0
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
First dose date up to Week 52 (responders) or Week 64 (non-responders) plus 30 days
Query!
Secondary outcome [5]
0
0
Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
First dose date up to Week 52 (responders) or Week 64 (non-responders) plus 30 days
Query!
Eligibility
Key inclusion criteria
Key
- Individuals assigned male at birth, or nonpregnant, nonlactating individuals assigned
female at birth, 18 to 75 years of age based on the date of the screening visit.
- Ulcerative colitis (UC) of at least 90-day duration before randomization confirmed by
endoscopy and histology at any time in the past AND a minimum disease extent of 15 cm
from the anal verge. Documentation of endoscopy and histology consistent with the
diagnosis of UC must be available in the source documents prior to the initiation of
screening.
- Moderately to severely active UC as determined during screening with a modified Mayo
Clinic Score based on the sum of Stool Frequency, Rectal Bleeding, and Endoscopic
Finding of 5 to 9 points and an endoscopic subscore of 2 to 3 (determined by central
reader).
- Previous treatment history of approved UC therapy with at least one advanced therapy
mechanisms of action but failure (ie, loss of response or lack of response) of no more
than 3 different advanced therapy mechanisms of action.
- Documentation of a surveillance colonoscopy in the 24 months prior to screening in
individuals who have a history of UC for 8 or more years.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Current diagnosis of Crohn's Disease (CD) or diagnosis of indeterminate colitis due to
an enteric pathogen, lymphocytic or collagenous colitis.
- Individuals with disease limited to the rectum (ulcerative proctitis) during screening
endoscopy.
- Requirement for ongoing therapy with or prior use of any prohibited medications.
- Active clinically significant infection, or any infection requiring hospitalization or
treatment with intravenous anti-infectives within 8 weeks.
of randomization; or any infection requiring oral anti-infective therapy within 6 weeks of
randomization.
- History of opportunistic infection.
- Current diagnosis of acute severe colitis, fulminant colitis, or toxic megacolon.
Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/12/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/06/2026
Query!
Actual
Query!
Sample size
Target
176
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Mater Adult Hospital - South Brisbane
Query!
Recruitment hospital [2]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Queen Elizabeth Hospital - Woodville
Query!
Recruitment hospital [4]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [4]
0
0
3168 - Clayton
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Minnesota
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oklahoma
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Vienna
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
London
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Toronto
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Vaughan
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Montpellier
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Nantes
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Toulouse
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Liepzig
Query!
Country [19]
0
0
Hungary
Query!
State/province [19]
0
0
Budapest
Query!
Country [20]
0
0
Italy
Query!
State/province [20]
0
0
Milano
Query!
Country [21]
0
0
Italy
Query!
State/province [21]
0
0
Rozzano
Query!
Country [22]
0
0
Japan
Query!
State/province [22]
0
0
Minato-ku
Query!
Country [23]
0
0
Japan
Query!
State/province [23]
0
0
Mitaka-shi
Query!
Country [24]
0
0
Japan
Query!
State/province [24]
0
0
Oita-shi
Query!
Country [25]
0
0
Japan
Query!
State/province [25]
0
0
Sagaken
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Sapporo
Query!
Country [27]
0
0
Korea, Republic of
Query!
State/province [27]
0
0
VIC
Query!
Country [28]
0
0
Korea, Republic of
Query!
State/province [28]
0
0
Busan
Query!
Country [29]
0
0
Korea, Republic of
Query!
State/province [29]
0
0
Daegu
Query!
Country [30]
0
0
Korea, Republic of
Query!
State/province [30]
0
0
Seoul
Query!
Country [31]
0
0
Korea, Republic of
Query!
State/province [31]
0
0
Wonju
Query!
Country [32]
0
0
Poland
Query!
State/province [32]
0
0
Sopot
Query!
Country [33]
0
0
Switzerland
Query!
State/province [33]
0
0
Bern
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
Bury
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
London
Query!
Country [36]
0
0
United Kingdom
Query!
State/province [36]
0
0
Norwich
Query!
Country [37]
0
0
United Kingdom
Query!
State/province [37]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is
effective and safe in treating participants with moderate to severe ulcerative colitis. The
study will compare participants in different treatment groups treated with tilpisertib
fosmecarbil with participants treated with placebo.
The primary objective of this study is to demonstrate the efficacy of tilpisertib
fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06029972
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Gilead Study Director
Query!
Address
0
0
Gilead Sciences
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Gilead Clinical Study Information Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-833-445-3230 (GILEAD-0)
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06029972
Download to PDF